1. Home
  2. VYGR vs UIS Comparison

VYGR vs UIS Comparison

Compare VYGR & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.74

Market Cap

194.0M

Sector

Health Care

ML Signal

HOLD

Logo Unisys Corporation New

UIS

Unisys Corporation New

HOLD

Current Price

$2.30

Market Cap

164.7M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
VYGR
UIS
Founded
2013
1942
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
194.0M
164.7M
IPO Year
2015
1994

Fundamental Metrics

Financial Performance
Metric
VYGR
UIS
Price
$3.74
$2.30
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$21.00
$5.67
AVG Volume (30 Days)
862.4K
818.5K
Earning Date
03-09-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,135,000.00
$1,950,100,000.00
Revenue This Year
$54.19
N/A
Revenue Next Year
$20.22
$2.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.65
$2.11
52 Week High
$5.55
$5.33

Technical Indicators

Market Signals
Indicator
VYGR
UIS
Relative Strength Index (RSI) 42.89 43.64
Support Level $3.36 $2.11
Resistance Level $3.74 $2.65
Average True Range (ATR) 0.32 0.10
MACD -0.06 0.01
Stochastic Oscillator 4.87 22.81

Price Performance

Historical Comparison
VYGR
UIS

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About UIS Unisys Corporation New

Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. maximum of revenue is from CA&I segment.

Share on Social Networks: